| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 57894-0514-01 | 57894-0514 | AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) | RYBREVANT FASPRO | 2240.0 mg/14mL, 28000.0 mg/14mL | Immunotherapy | Monoclonal Antibody | EGFR, MET | Subcutaneous | Dec 19, 2025 | In Use | |
| 57894-0522-01 | 57894-0522 | AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) | Rybrevant Faspro | 3520.0 mg/22mL, 44000.0 mg/22mL | Immunotherapy | Monoclonal Antibody | EGFR, MET | Subcutaneous | Feb 13, 2026 | In Use | |
| 65219-0672-01 | 65219-0672 | Denosumab | BOMYNTRA | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 30, 2025 | In Use | |
| 78206-0193-01 | 78206-0193 | Denosumab | BILDYOS | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 11, 2025 | In Use | |
| 70720-0950-36 | 70720-0950 | Goserelin | ZOLADEX | 3.6 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | Mar 31, 2018 | In Use | ||
| 83634-0454-61 | 83634-0454 | Leuprolide acetate | Leuprolide Acetate | 5.0 mg/mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Oct 15, 2025 | Jun 30, 2026 | No Longer Used | |
| 70771-1776-01 | 70771-1776 | Plerixafor | PLERIXAFOR | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jul 28, 2023 | In Use | |
| 44206-0457-22 | 44206-0457 | Human Immunoglobulin G | Hizentra | 0.2 g/mL | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | Subcutaneous | Jan 1, 2020 | In Use | |
| 76282-0720-67 | 76282-0720 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | May 30, 2025 | In Use | ||
| 69448-0026-63 | 69448-0026 | Pegfilgrastim-cbqv | UDENYCA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 23, 2026 | In Use | |
| 00004-0360-09 | 00004-0360 | Peginterferon alfa-2a | Pegasys | 135.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Nov 1, 2011 | Feb 8, 2018 | No Longer Used |
| 50242-0108-86 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 23, 2017 | In Use | |
| 50242-0109-01 | 50242-0109 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 22, 2017 | In Use | |
| 55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 5, 2010 | In Use | |
| 63459-0918-59 | 63459-0918 | tbo-filgrastim | GRANIX | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 7, 2018 | In Use | |
| 72893-0016-02 | 72893-0016 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
| 15054-0090-01 | 15054-0090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov 14, 2007 | Aug 31, 2016 | No Longer Used | |
| 00024-0605-45 | 00024-0605 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 23, 2002 | May 31, 2016 | No Longer Used | ||
| 57894-0503-01 | 57894-0503 | Daratumumab and hyaluronidase-fihj (human recombinant) | Darzalex Faspro | 1800.0 mg/15mL, 4.9 mg/15mL, 18.4 mg/15mL, 30000.0 U/15mL, 13.5 mg/15mL, 6.0 mg/15mL, 735.1 mg/15mL | Immunotherapy | Monoclonal Antibody | CD38 | Subcutaneous | May 1, 2020 | In Use | |
| 61314-0866-02 | 61314-0866 | Pegfilgrastim-bmez | ZIEXTENZO | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | Subcutaneous | Mar 3, 2025 | In Use | |
| 31722-0373-31 | 31722-0373 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jun 16, 2025 | In Use | |
| 57377-0060-01 | 57377-0060 | Testosterone,USP | Testozole | 4.0 mg/1, 60.0 mg/1 | Hormonal Therapy | Androgen/Aromatase Inhibitor | Subcutaneous | Jan 1, 2021 | In Use | ||
| 50242-0245-01 | 50242-0245 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | Jun 29, 2020 | In Use | |
| 70383-0073-01 | 70383-0073 | MOTIXAFORTIDE ACETATE | Aphexda | 62.0 mg/1.7mL | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | Subcutaneous | Sep 8, 2023 | In Use | |
| 15054-1060-03 | 15054-1060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov 14, 2007 | Jun 30, 2022 | In Use |
Found 12611 results — Export these results
Home